Tue. 14 May 2024, 4:26pm ET
Benzinga
Earnings, Earnings Beats, News
Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.42) by 40.48 percent. The company reported quarterly sales of $28.14 million which beat the analyst consensus estimate of $11.67 million by 141.22 percent. This is a 172.09 percent increase over sales of $10.34 million the same period last year.